US Drug Recall Register
Class II · Moderate risk Terminated Initiated May 1, 2018 (8 years ago)

Loxapine Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

What was recalled

Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-903-20.

Recalling firm
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
NDC code
51079-903-20
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0823-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Pine recalls

See all
Class II · Moderate risk Ongoing

Amlodipine and Olmesartan Medoxomil Tablets

Reason Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Ascend Laboratories, LLC D-0712-2026
Class II · Moderate risk Ongoing

Cleviprex

Reason Lack of Assurance of Sterility

Chiesi USA, Inc. NDC 10122-611-10 D-0689-2026
Class III · Low risk Ongoing

Epinephrine Injection

Reason Failed Impurities/Degradations Specifications

Fresenius Kabi USA, LLC NDC 63323-696-02 D-0581-2026
Class II · Moderate risk Ongoing

Amlodipine and Olmesartan Medoxomil Tablets

Reason Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications

Ascend Laboratories, LLC NDC 67877-501-30 D-0556-2026
Class II · Moderate risk Ongoing

EPINEPHRINE Injection

Reason Lack of Assurance of Sterility

International Medication Systems Ltd. NDC 76329-3318-1 D-0483-2026